Syntara Ltd Cash Flow Conversion Efficiency
Syntara Ltd cash flow conversion efficiency. Based on the latest financial reports, Syntara Ltd (SNT) has a cash flow conversion efficiency ratio of -0.694x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-11.12 Million ≈ $-7.86 Million USD) by net assets (AU$16.02 Million ≈ $11.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Syntara Ltd (2004–2023)
Cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. This chart illustrates how Syntara Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Syntara Ltd stock quote for real-time trading data and today's change.
Syntara Ltd Cash Flow Conversion Ratio Explained
Syntara Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Syntara Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syntara Ltd ranked by their cash flow conversion efficiency. Also see SNT company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uniserve Communications Corp
V:USS
|
-0.071x |
|
Cruzados SADP
SN:CRUZADOS
|
-0.021x |
|
Kintech Electronics Co Ltd
TWO:6210
|
-0.056x |
|
Mountain Alliance AG
XETRA:ECF
|
-0.020x |
|
Eastparc Hotel Tbk PT
JK:EAST
|
0.017x |
|
MegaMD Co. Ltd
KQ:133750
|
-0.005x |
|
Deep Value Driller AS
OL:DVD
|
1.304x |
|
Milestone Scientific
NYSE MKT:MLSS
|
0.032x |
Annual Cash Flow Conversion Efficiency for Syntara Ltd (2004–2023)
The table below shows the annual cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. Review SNT free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | AU$9.56 Million ≈ $6.76 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-0.761x | +49.55% |
| 2022-06-30 | AU$10.80 Million ≈ $7.64 Million |
AU$-16.30 Million ≈ $-11.54 Million |
-1.509x | -239.75% |
| 2021-06-30 | AU$2.85 Million ≈ $2.01 Million |
AU$3.07 Million ≈ $2.17 Million |
1.080x | +111.63% |
| 2020-06-30 | AU$1.43 Million ≈ $1.01 Million |
AU$-13.28 Million ≈ $-9.40 Million |
-9.283x | -594.61% |
| 2019-06-30 | AU$14.81 Million ≈ $10.48 Million |
AU$-19.80 Million ≈ $-14.01 Million |
-1.336x | -221.73% |
| 2018-06-30 | AU$11.12 Million ≈ $7.87 Million |
AU$12.21 Million ≈ $8.64 Million |
1.098x | +125.33% |
| 2017-06-30 | AU$3.52 Million ≈ $2.49 Million |
AU$-15.26 Million ≈ $-10.80 Million |
-4.335x | -656.57% |
| 2016-06-30 | AU$20.93 Million ≈ $14.81 Million |
AU$-11.99 Million ≈ $-8.48 Million |
-0.573x | -195.54% |
| 2015-06-30 | AU$36.32 Million ≈ $25.70 Million |
AU$21.78 Million ≈ $15.41 Million |
0.600x | +138.51% |
| 2014-06-30 | AU$18.07 Million ≈ $12.78 Million |
AU$-28.13 Million ≈ $-19.91 Million |
-1.557x | -198.78% |
| 2013-06-30 | AU$67.89 Million ≈ $48.04 Million |
AU$-35.38 Million ≈ $-25.04 Million |
-0.521x | -50.03% |
| 2012-06-30 | AU$109.80 Million ≈ $77.69 Million |
AU$-38.14 Million ≈ $-26.99 Million |
-0.347x | +34.15% |
| 2011-06-30 | AU$70.83 Million ≈ $50.12 Million |
AU$-37.37 Million ≈ $-26.44 Million |
-0.528x | -52.90% |
| 2010-06-30 | AU$115.02 Million ≈ $81.38 Million |
AU$-39.68 Million ≈ $-28.08 Million |
-0.345x | -79.48% |
| 2009-06-30 | AU$137.69 Million ≈ $97.43 Million |
AU$-26.47 Million ≈ $-18.73 Million |
-0.192x | -21.48% |
| 2008-06-30 | AU$119.12 Million ≈ $84.29 Million |
AU$-18.85 Million ≈ $-13.34 Million |
-0.158x | +41.47% |
| 2007-06-30 | AU$76.56 Million ≈ $54.17 Million |
AU$-20.70 Million ≈ $-14.64 Million |
-0.270x | -94.07% |
| 2006-06-30 | AU$98.89 Million ≈ $69.97 Million |
AU$-13.78 Million ≈ $-9.75 Million |
-0.139x | +46.58% |
| 2005-06-30 | AU$35.57 Million ≈ $25.17 Million |
AU$-9.27 Million ≈ $-6.56 Million |
-0.261x | -50.10% |
| 2004-06-30 | AU$26.78 Million ≈ $18.95 Million |
AU$-4.65 Million ≈ $-3.29 Million |
-0.174x | -- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more